Garnett Timothy John
CIK: 0001998937
Garnett Timothy John's purchase track record
Garnett Timothy John has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/10/2026 | MPLT | $253K | +69.4% | -33.0% | +11.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MPLT | ▲ Buy | Grant | 3,932 | $0 | 6/23/2026 | View on chart |
| MPLT | ▲ Buy | Open Market | 14,124 | $253K | 2/10/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 6,294 | $0 | 10/27/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.